SIALYLATION OF ANTI-HISTONE ANTIBODIES IN BLOOD SERUM OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS



I. B. Mahorivska, R. O. Bilyy, L. Muñoz, M. Herrmann, R. S. Stoika, Yu. Ya. Kit


DOI: http://dx.doi.org/10.30970/sbi.0603.239

Abstract


Anti-histone autoantibodies belong to main marker antibodies used in the diagnostics of systemic lupus erythematosus (SLE) patients. During autoimmune diseases, especially in SLE, prevalent process of inflammation is caused by high titers of auto-antibodies. It is known that the level of IgG sialylation affect their anti-inflammatory properties. The aim of the experiments was to investigate the level of sialylation of anti-histone IgG-antibodies from blood serum of patients with SLE. Investigation was carried out by two methodological approaches. In the first case, the antibodies were purified from blood serum by affine chromatography on histone-Sepharose and protein G-Sepharose followed by Western blot detection of sialic acid residues in the carbohydrate chaines of IgG molecules using sialospecific previously biotinylated Sambucus nigra lectin (SNA). In the second case, IgG-antibodies were isolated from blood serum by affine chromato­graphy on protein G-Sepharose, this fraction was separated on sialylated and not sialy­lated IgG by SNA-Sepharose chromatography followed by checking their affinity to histones by ELISA. In this manuscript, it is shown that the level of sialylation of anti-histone IgG is lower than in control preparation of antibodies. Our data showed that anti-histone autoantibodies are devoid of sialic acid residues at the ends of the carbohydrate chains of Fc-fragments promote their inflammatory properties in patients with SLE.

Note: ELISA – enzyme linked immunosorbent assay, Ab – antibodies, auto-Ab – auto-antibodies.


Keywords


blood serum, anti-histone auto-antibodies, systemic lupus erythematosus, carbohydrate chains, sialic acid residues

References


1. Dimitrov J.D., Bayry J., Siberil S., Kaveri S.V. Sialylated therapeutic IgG: a sweet remedy for inflammatory diseases? Nephrol. Dial. Transplant, 2007; 22(5): 1301-4.
https://doi.org/10.1093/ndt/gfl847
PMid:17298999

2. Lim P.L., Zouali M. Pathogenic autoantibodies: emerging insights into tissue injury. Immunol. Lett, 2006; 103(1): 17-26.
https://doi.org/10.1016/j.imlet.2005.10.023
PMid:16325269

3. Scanlan C.N., Burton D.R., Dwek R.A. Making autoantibodies safe. Proc. Natl. Acad. Sci USA, 2008; 105(11): 4081-2.
https://doi.org/10.1073/pnas.0801192105
PMid:18344326 PMCid:PMC2393817

4. Anthony R.M., Ravetch J.V. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J. Clin. Immunol, 2010; 30(Suppl 1): S9-14.
https://doi.org/10.1007/s10875-010-9405-6
PMid:20480216

5. Albert H., Collin M., Dudziak D. et al. In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc. Natl. Acad. Sci. USA, 2008; 105(39): 15005-9.
https://doi.org/10.1073/pnas.0808248105
PMid:18815375 PMCid:PMC2567483

6. Kaneko Y., Nimmerjahn F., Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science, 2006; 313(5787): 670-3.
https://doi.org/10.1126/science.1129594
PMid:16888140

7. Butler M., Quelhas D., Critchley A.J. et al. Detailed glycan analysis of serum glycoproteins of patients with congenital disorders of glycosylation indicates the specific defective glycan processing step and provides an insight into pathogenesis. Glycobiology, 2003; 13(9): 601-22.
https://doi.org/10.1093/glycob/cwg079
PMid:12773475

8. Nimmerjahn F., Anthony R.M., Ravetch J.V. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc. Natl. Acad. Sci. USA, 2007; 104(20): 8433-7.
https://doi.org/10.1073/pnas.0702936104
PMid:17485663 PMCid:PMC1895967

9. Anthony R.M., Wermeling F., Ravetch J.V. Novel roles for the IgG Fc glycan. Ann NY Acad. Sci, 2012; 1253: 170-80.
https://doi.org/10.1111/j.1749-6632.2011.06305.x
PMid:22288459

10. Bach J.F., Koutouzov S., Van Endert P.M. Are there unique autoantigens triggering autoimmune diseases? Immunol. Rev, 1998; 164: 139-55.
https://doi.org/10.1111/j.1600-065X.1998.tb01216.x
PMid:9795772

11. Isenberg D.A. Systemic lupus erythematosus: immunopathogenesis and the card game analogy. J. Rheumatol. Suppl, 1997; 48: 62-6.

12. Tan E.M. Antinuclear antibodies: diagnostic markers and clues to the basis of systemic autoimmunity. Pediatr. Infect. Dis. J, 1988; 7(5 Suppl): S3-9.
https://doi.org/10.1097/00006454-198805001-00002

13. Kubota T. [Advances in systemic lupus erythematosus]. Nihon Rinsho, 1999; 57(2): 329-32.

14. Nezlin R., Alarcon-Segovia D., Shoenfeld Y. Immunochemical determination of DNA in immune complexes present in the circulation of patients with systemic lupus erythematosus. J. Autoimmun, 1998; 11(5): 489-93.
https://doi.org/10.1006/jaut.1998.0231
PMid:9802934

15. Nimmerjahn F., Ravetch J.V. The antiinflammatory activity of IgG: the intravenous IgG paradox. J. Exp. Med, 2007; 204(1): 11-5.
https://doi.org/10.1084/jem.20061788
PMid:17227911 PMCid:PMC2118416

16. Magorivska I.B., Bilyy R.O., Havrylyuk A.M. et al. Anti-histone H1 IgGs from blood serum of systemic lupus erythematosus patients are capable of hydrolyzing histone H1 and myelin basic protein. J. Mol. Recognit, 2010; 23(5): 495-502.
https://doi.org/10.1002/jmr.1033
PMid:20583146

17. Anthony R.M., Nimmerjahn F., Ashline D.J. et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science, 2008; 320(5874): 373-6.
https://doi.org/10.1126/science.1154315
PMid:18420934 PMCid:PMC2409116

18. Tan E.M. Pathophysiology of antinuclear antibodies in systemic lupus erythematosus and related diseases. Adv. Dent. Res, 1996; 10(1): 44-6.
https://doi.org/10.1177/08959374960100010801
PMid:8934923

19. Stadlmann J., Weber A., Pabst M. et al. A close look at human IgG sialylation and subclass distribution after lectin fractionation. Proteomics, 2009; 9(17): 4143-53.
https://doi.org/10.1002/pmic.200800931
PMid:19688751

20 Bilyy R., Tomin A., Tolstyak Ya. et al. Cell Surface Glycans at SLE - Changes during cells death, utilization for disease detection and molecular mechanism underlying their modification. In Autoimmune Disorders - Pathogenetic Aspects / ed.: Mavragany C.P. InTech, Rijeka, Croatia, 2011. P. 89-110.

21. Shkandina T., Herrmann M., Bilyy R. Sweet kiss of dying cell: Sialidase activity on apoptotic cell is able to act toward its neighbors. Autoimmunity, 2012 (PMID: 22928616).
https://doi.org/10.3109/08916934.2012.719951
PMid:22928616

22. Bilyy R., Tomin A., Mahorivska I. et al. Antibody-mediated sialidase activity in blood serum of patients with multiple myeloma. J. Mol. Recognit, 2011; 24: 576-584.
https://doi.org/10.1002/jmr.1071
PMid:21472809


Refbacks

  • There are currently no refbacks.


Copyright (c) 2012 Studia biologica

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.